Trypanosoma cruzi Adjuvants Potentiate T Cell-Mediated Immunity Induced by a NY-ESO-1 Based Antitumor Vaccine


Autoria(s): Junqueira, Caroline; Guerrero, Ana Tereza; Galvao-Filho, Bruno; Andrade, Warrison A.; Salgado, Ana Paula C.; Cunha, Thiago M.; Ropert, Catherine; Campos, Marco Antonio; Penido, Marcus L. O.; Mendonca-Previato, Lucia; Previato, Jose Oswaldo; Ritter, Gerd; Cunha, Fernando Q.; Gazzinelli, Ricardo T.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

05/11/2013

05/11/2013

2012

Resumo

Immunological adjuvants that induce T cell-mediate immunity (TCMI) with the least side effects are needed for the development of human vaccines. Glycoinositolphospholipids (GIPL) and CpGs oligodeoxynucleotides (CpG ODNs) derived from the protozoa parasite Trypanosoma cruzi induce potent pro-inflammatory reaction through activation of Toll-Like Receptor (TLR) 4 and TLR9, respectively. Here, using mouse models, we tested the T. cruzi derived TLR agonists as immunological adjuvants in an antitumor vaccine. For comparison, we used well-established TLR agonists, such as the bacterial derived monophosphoryl lipid A (MPL), lipopeptide (Pam3Cys), and CpG ODN. All tested TLR agonists were comparable to induce antibody responses, whereas significant differences were noticed in their ability to elicit CD4(+) T and CD8(+) T cell responses. In particular, both GIPLs (GTH, and GY) and CpG ODNs (B344, B297 and B128) derived from T. cruzi elicited interferon-gamma (IFN-gamma) production by CD4(+) T cells. On the other hand, the parasite derived CpG ODNs, but not GIPLs, elicited a potent IFN-gamma response by CD8(+) T lymphocytes. The side effects were also evaluated by local pain (hypernociception). The intensity of hypernociception induced by vaccination was alleviated by administration of an analgesic drug without affecting protective immunity. Finally, the level of protective immunity against the NY-ESO-1 expressing melanoma was associated with the magnitude of both CD4+ T and CD8+ T cell responses elicited by a specific immunological adjuvant.

Atlantic Philanthropies/Ludwig Institute for Cancer Research (LICR) - Clinical Discovery Program

Atlantic Philanthropies/Ludwig Institute for Cancer Research (LICR) Clinical Discovery Program

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil (CNPq) - Instituto Nacional de Ciencia e Tecnologia de Vacinas

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil (CNPq) Instituto Nacional de Ciencia e Tecnologia de Vacinas

Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG), Brazil

Fundacao de Amparo a Pesquisa do Estado de Minas Gerais, Brazil (FAPEMIG

Identificador

PLOS ONE, SAN FRANCISCO, v. 7, n. 5, supl. 1, Part 2, pp. 110-115, MAY 2, 2012

1932-6203

http://www.producao.usp.br/handle/BDPI/41079

10.1371/journal.pone.0036245

http://dx.doi.org/10.1371/journal.pone.0036245

Idioma(s)

eng

Publicador

PUBLIC LIBRARY SCIENCE

SAN FRANCISCO

Relação

PLOS ONE

Direitos

openAccess

Copyright PUBLIC LIBRARY SCIENCE

Palavras-Chave #PATTERN-RECOGNITION RECEPTORS #REDUCING INJECTION PAIN #TOLL-LIKE RECEPTORS #HOST-RESISTANCE #INNATE IMMUNITY #PROINFLAMMATORY CYTOKINES #ADAPTIVE IMMUNITY #INTERFERON-GAMMA #DENDRITIC CELLS #TLR9 AGONISTS #MULTIDISCIPLINARY SCIENCES
Tipo

article

original article

publishedVersion